Berry Genomics Co.,Ltd (000710.SZ)

CNY 10.25

(-2.38%)

Market Cap (In CNY)

3.62 Billion

Revenue (In CNY)

1.15 Billion

Net Income (In CNY)

-427.19 Million

Avg. Volume

15.21 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.4-13.16
PE
-11.82
EPS
-0.8
Beta Value
0.699
ISIN
CNE000000PN7
CUSIP
-
CIK
-
Shares
353521000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Yang Gao
Employee Count
-
Website
https://www.berrygenomics.com
Ipo Date
1997-04-22
Details
Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.